Evidence map›Paper›PMID 41062835›Full record

ArticleNature chemical biology2026

Stabilization of AFF1 by PARylation ensures transcriptional restart after DNA damage.

Feifeng Zhu, Huanyi Fu, Wenxuan Zhu, Chengyu Li, Min Yang, Zeming Feng, Yangqing Shao, Zhuo Li, Yafei Guo, Mengting Huang and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. PANoptosis: potential new targets and therapeutic prospects in digestive diseases.Apoptosis : an international journal on programmed cell death · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Feifeng Zhu *Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Affiliated Xiamen Eye Center & Xiang'an Hospital, Xiamen University, Xiamen, China.ORCID http://orcid.org/0009-0008-8084-7282
Huanyi Fu *Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.
Wenxuan Zhu *Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.
Chengyu Li *Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.
Min YangZhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.
Zeming FengZhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0002-8564-896X
Yangqing ShaoZhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0009-0002-7010-8714
Zhuo LiZhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.
Yafei GuoFujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Affiliated Xiamen Eye Center & Xiang'an Hospital, Xiamen University, Xiamen, China.
Mengting HuangFujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Affiliated Xiamen Eye Center & Xiang'an Hospital, Xiamen University, Xiamen, China.
Yitong ZhangZhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.
Yaohui HeFujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Affiliated Xiamen Eye Center & Xiang'an Hospital, Xiamen University, Xiamen, China.ORCID http://orcid.org/0000-0002-8235-8924
Yi LuTongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID http://orcid.org/0000-0002-1599-8593
Zhibing WuDepartment of Oncology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0003-2059-7142
Qiang ZhouSchool of Biological Sciences, Faculty of Science, The University of Hong Kong, Hong Kong, China.
Huipeng JiaoZhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0001-9632-6176
Jun HuangZhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0002-7837-653X
Long ZhangZhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0001-8139-0474
Yuhua XueFujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Affiliated Xiamen Eye Center & Xiang'an Hospital, Xiamen University, Xiamen, China. xueyuhua@xmu.edu.cn.ORCID http://orcid.org/0000-0001-5804-5162
Huasong LuZhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China. huasong_lu@zju.edu.cn.ORCID http://orcid.org/0000-0003-0875-5531

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32370591Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LRG25C060001
6 · The paper itself

Abstract

Precise control of transcription is essential for cell survival under stress conditions, including DNA damage. While mechanisms of DNA damage-induced transcriptional silencing are well characterized, how transcription resumes remains less understood. Here we identify a new role for poly(ADP-ribose) polymerase 1 (PARP1) in transcriptional restart during the DNA damage response (DDR) through a mechanism termed poly(ADP-ribose)-mediated stabilization (PARSTA) of AFF1. Upon DNA damage, PARP1 binds to and PARylates AFF1 in a region targeted by the E3 ligase Siah1, preventing AFF1 ubiquitination and promoting its stability. This stabilization supports efficient transcriptional recovery after DNA damage. Notably, cells resistant to genotoxic stress exhibit elevated PARP1 activity and AFF1 levels, while AFF1 depletion impairs DNA repair and survival. Together, these findings expand PARP1's role to the transcriptional recovery phase in DDR and suggest that targeting the PARSTA pathway may offer therapeutic potential in diseases characterized by hyperactive PARP1 and elevated levels of AFF1.

Indexed as

DNA DamageNuclear ProteinsPoly (ADP-Ribose) Polymerase-1Poly ADP RibosylationTranscription, GeneticDNA RepairHumansProtein StabilitySeven in Absentia ProteinsUbiquitinationUbiquitin-Protein LigasesNuclear ProteinsPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Seven in Absentia ProteinsUbiquitin-Protein Ligases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.